Nursing and Health Professions
Quality of Life
90%
Patient
81%
Capecitabine
72%
Lapatinib
54%
Diseases
18%
Group Therapy
18%
Functional Assessment
18%
Neoplasm
18%
Metastatic Breast Cancer
18%
Time
18%
Cancer Therapy
18%
Follow up
9%
Visual Analog Scale
9%
Breast Cancer
9%
Combination Therapy
9%
Patient Population
9%
Screening
9%
Quality of Life Assessment
9%
Analysis
9%
Trastuzumab
9%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
9%
INIS
quality of life
100%
patients
90%
cancer
45%
breasts
45%
comparative evaluations
36%
assessments
27%
therapy
27%
tumors
18%
diseases
18%
metastases
18%
screening
9%
populations
9%
risk assessment
9%
Pharmacology, Toxicology and Pharmaceutical Science
Capecitabine
72%
Lapatinib
54%
Diseases
18%
Neoplasm
18%
Metastatic Breast Cancer
18%
Breast Cancer
9%
Trastuzumab
9%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
9%
Safety Assessment
9%
Efficacy Assessment
9%